Co-founder of more than 40 biotechnology companies, including 16 IPOs and 19 successful acquisitions Scientific and medical titan focused on driving innovation for human healthWill assist with ...
Co-founder of more than 40 biotechnology companies, including 16 IPOs and 19 successful acquisitions Scientific and medical titan focused on driving innovation for human healthWill assist with listeri ...
A multi-institute research team led by Nagaland University has identified anti-cancer potential in a traditional five-plant ...
Combination therapy led to complete remission in more than 50% of mice with different tumor types, many of which were resistant to ICB therapy alone.
A new review reveals how focal adhesion kinase (FAK) acts as a central regulator of tumor progression and immune suppression ...
Boehringer Ingelheim today announced a clinical trial collaboration with BioNTech to evaluate a novel immuno--oncology combination in extensive--stage small cell lung cancer (ES-SCLC), one of the most ...
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab) ...
Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed ...
A new comprehensive review is shedding light on the expanding role of focal adhesion kinase (FAK) in cancer biology and its potential as a ...
A new drug candidate has been developed that simultaneously blocks the proteins regulating cancer growth and metastasis. In ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ('HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several ...
Boehringer Ingelheim to evaluate combination of DLL3-targeting T-cell engager plus PD-L1/VEGF-A bispecific antibody in small cell lung cancer: Ingelheim, Germany Saturday, April 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results